Form 4: Ocular Therapeutix Director Charles M. Warden Receives Stock Grants and Options

Director Charles M. Warden of Ocular Therapeutix, Inc. was granted 12,000 restricted stock units and options to purchase 36,000 shares of common stock on July 24, 2024.

Summary

• Charles M. Warden, a director of Ocular Therapeutix, Inc., received grants of restricted stock units (RSUs) and stock options on July 24, 2024.
• He was granted 12,000 RSUs under the company's 2021 Stock Incentive Plan, as amended.
• Each RSU represents the right to receive one share of Ocular Therapeutix's common stock.
• The RSUs will vest on the first anniversary of the grant date or immediately before the next annual meeting of stockholders, contingent upon Warden's continued service on the board.
• Warden also received options to purchase 36,000 shares of common stock at an exercise price of $7.91 per share.
• These options also vest on the first anniversary of the grant date or immediately before the next annual meeting of stockholders, subject to continued service.
• Following these transactions, Warden directly owns 72,464 shares of Ocular Therapeutix common stock and options to purchase 36,000 shares.
• The options expire on 07/23/2034.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, indicating stability and alignment of interests. It's a neutral positive.

Positives

• The grant of RSUs and stock options to a director aligns his interests with those of the shareholders.
• The vesting schedule incentivizes continued service on the board of directors.

Future Outlook

The RSUs and stock options will vest on the first anniversary of the grant date or immediately before the next annual meeting of stockholders, contingent upon Warden's continued service on the board.

Industry Context

Stock grants and options are common forms of compensation for directors in publicly traded companies, aligning their interests with shareholders and incentivizing company performance.

Comparison to Industry Standards

• Director compensation packages, including stock options and RSUs, are standard practice among publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• Companies like Alnylam Pharmaceuticals and Vertex Pharmaceuticals also utilize similar equity-based compensation to incentivize their board members.
• The vesting schedules, typically one year or aligned with annual meetings, are also consistent with industry norms.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align the director's interests with the company's long-term success.
• The grants do not have an immediate impact on employees, customers, suppliers, or creditors.

Key Dates